Currently, there are three CAR-T cell platforms targeting CD19 approved by the US Food and Drug Administration (FDA) for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) in pediatric and young adults (Kymriah®), for the treatment of relapsed or refractory diffused large B-cell lymphoma (DLBCL) in adults (Kymriah® and Yescarta®), and for the treatment of relapsed or refractory mantle cell lymphoma (MCL) in adults (TecartusTM). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.